课题基金 / 基金详情

TAP-1/E7 INTERACTION: ROLE IN RESPIRATORY PAPILLOMAS

TAP-1/E7 INTERACTION: ROLE IN RESPIRATORY PAPILLOMAS
TAP-1/E7 相互作用:在呼吸道乳头状瘤中的作用
批准号:
6603273
负责人:
Andrea Vambutas
金额:
$7.9万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-01 至 2005-04-30

项目摘要

项目成果

Andrea Vambutas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Laryngeal papillomatosis is a Human Papillomavirus (HPV) mediated disease characterized by multiple recurrences and frequent surgeries to maintain an airway. We have found that these infected cells have an impaired ability to present antigen to circulating CD8 T cells. TAP-1 (the Transporter Associated with Antigen Presentation) appeared to be reduced in laryngeal papillomatosis (HPV type 6111). Intriguing new results have lead us to postulate that this key transporter responsible for antigen presentation may not be lacking, but rather, because of an interaction with the E7 viral protein, TAP-1 is unavailable. This interaction imparts a functional consequence: purified HPV 11 E7 protein inhibited ATP-dependent peptide transport in vitro. The TAP-1 E7 interaction observed in HPV 11 seems to occur with HPV 16 as well, according to preliminary immunoprecipitation data, which has lead us to our hypothesis: we hypothesize that one of the conserved domains of E7 interact with TAP-1 and functionally disables it. This application has three specific aims to test the hypothesis: 1. To determine the critical region of HPV 11 E7 necessary for a physical interaction with TAP-1 and analyze whether this critical region also imparts functional inhibition of the transporter. 2. To determine if polymorphisms of TAP-1 or E7 can partially account for variations in disease susceptibility. 3. To determine whether the interaction between TAP-1 and E7 in naturally occurring infections sufficient to result in a loss of peptide transport and whether this loss correlates with viral protein load and the patients clinical course.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A phase I clinical trial of Anakinra for Steroid-Resistant AIED
A phase I clinical trial of Anakinra for Steroid-Resistant AIED
A phase I clinical trial of Anakinra for Steroid-Resistant AIED
A phase I clinical trial of Anakinra for Steroid-Resistant AIED
海外基金